CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

ICICI Prudential Life Insurance launches new retirement pension plan

DSIJ Intelligence 0 3625 Article rating: 4.6

On Friday, ICICI Prudential Life Insurance announced that it has launched an innovative retirement plan, offering guaranteed life-long income. The plan is a non-linked non-participating individual annuity product, which provides its customers with an option to choose between immediate and deferred annuity.

Strides Pharma rises nearly 3 per cent on receiving USFDA nod for Oxybutynin Chloride tablets

DSIJ Intelligence 0 1010 Article rating: 4.0

Strides Pharma Science today announced that its wholly-owned subsidiary, Strides Pharma Global Pte Ltd (Singapore) has received approval for Oxybutynin Chloride tablets USP, 5 mg from United States Food & Drug Administration (USFDA). The tablet is therapeutically and bioequivalent equivalent to the reference listed drug (RLD), Ditropan tablets, 5 mg, of Janssen Pharmaceuticals, Inc.

Nifty trend for Friday

DSIJ Intelligence-3 0 1458 Article rating: 4.5

No prizes for guessing! Nifty formed yet another indecisive candlestick pattern on the daily chart today. It’s more or less like hitting 6 sixes in 6 balls as for the sixth day in a row, Nifty has formed this pattern. There are high chances that we would once again enter into a phase of consolidation after hitting the targets of 13,800-13,840.

Where To Invest In : 2021

Ninad Ramdasi 0 1781 Article rating: 4.3

Very few years in the history of equity markets have been as eventful as 2020. That makes 2021 extremely interesting for both bears and bulls as the markets are precariously poised at record highs. Geyatee Deshpande discusses how the year 2020 has been for equity investors and Vinayak Gangule shares his technical view on the markets while Yogesh Supekar forecasts what one can expect in 2021 even as the DSIJ research team highlights its ‘where to invest in 2021’ portfolio in this cover story 

Kerbside

Ninad Ramdasi 0 852 Article rating: No rating

The recommendations provided in this column are taken from various market sources such as brokers, analysts, dealers and investment strategists, etc. These recommendations may not be backed by strong fundamentals.

Review

Ninad Ramdasi 0 847 Article rating: No rating

In this edition, we have reviewed KNR Constructions Ltd. and National Aluminium Company Ltd. We suggest our reader-investors to HOLD in KNR Constructions Ltd. and National Aluminium Company Ltd.

Data Bank & Dividend

Ninad Ramdasi 0 1016 Article rating: No rating

This is a super house of financial data on 3500 corporates with up to date information. In the Magazine version the top 1100 -1400 companies are covered while the data on the entire 3500 companies is available in excel format for subscribers to download.

MF Query Board

Ninad Ramdasi 0 583 Article rating: No rating

Readers are requested to send only one query at a time so that more readers get a chance. Have questions relating to any aspect of personal finance. Ask DSIJ at editorial@DSIJ.in and get your queries resolved.

Fund of Fortnight

Ninad Ramdasi 0 946 Article rating: No rating

This is our mutual fund recommendation. Every fortnight ,we recommend one open-ended equity diversified fund that has the best potential of returns for the next one year considering its constituents remain the same.

Know Thyself!

Ninad Ramdasi 0 502 Article rating: No rating

One of the world's biggest investment research and investment management services' companies did a study about how the average investor fared in a fund over a period of time.

Mid-Cap Funds

Ninad Ramdasi 0 970 Article rating: No rating

Your cover story Mid Cap Funds a Better Choices' was quite insightful. However, if my investment horizon is five years from today, then would investing in mid cap funds make sense?

Markets may open on a soft note; follow stock-specific approach in todays session

DSIJ Intelligence-3 0 1146 Article rating: 4.3

On Wednesday, Indian markets displayed a strong performance as Nifty witnessed a breakout of the consolidation range while the key benchmark indices ended the day at record highs. However, on Thursday morning, SGX Nifty is indicating a soft opening as the global cues are not encouraging. SGX Nifty was trading down by 17 points at 13,668 levels.

Stocks that are likely to record significant movement on bourses today

DSIJ Intelligence-3 0 1313 Article rating: 4.4

Hero MotoCorp: There has been a steady rise in commodity costs across the spectrum, including steel, aluminium, plastics, and precious metals. In order to partially offset the impact of the commodity costs, the company will be increasing the prices of its products by up to Rs 1,500, with effect from January 1, 2021. The increase will vary across models, and the exact quantum will be communicated to dealers in due course.

PNB slumps 6 per cent on announcing QIP issue floor price

DSIJ Intelligence 0 1382 Article rating: 3.4

The shares of Punjab National Bank (PNB) fell as much as 6 per cent on Wednesday, continuing the trend seen in the last two days after the bank announced the opening of qualified institutional placement (QIP) issue. The price of the state-owned lender fell below the QIP flow price of Rs 37.35 during today’s early trading session before showing some recovery.

Mahindra & Mahindra rises over 3 per cent post announcing price increase of vehicles

DSIJ Intelligence 0 669 Article rating: 5.0

Mahindra & Mahindra Ltd (M&M) announced on Tuesday after the market hours that the company is planning to increase the price of its range of passenger & commercial vehicles across models with effect from January 1, 2021. The company has done this as a result of an increase in commodity prices and other input costs.

SGX Nifty indicates fresh record highs on back of hopes for US stimulus breakthrough

DSIJ Intelligence-3 0 757 Article rating: 4.5

Tuesday was all about the turnaround on D-Street as the key benchmark indices reversed their losses and eked out modest gains. In the current scenario, the bulls seem to have conditioned to buy a dip and there is no point in fighting the trend.

Nifty trend for Wednesday

DSIJ Intelligence-3 0 1172 Article rating: 4.4

The trend of the index is up, and as long as it trades above the 13,400 mark dips, it would attract buyers while on the upside, the zone of 13,600-13,650 is a strong resistance zone for fresh momentum index, which needs to move above this resistance zone.

Sensex, Nifty close with minimal gains; KNR Constructions gains more than 5 per cent, Majesco announces dividend

DSIJ Intelligence 0 1225 Article rating: 2.8

On Tuesday, the domestic markets witnessed a highly volatile session. Sensex recovered by 421.5 points from the day’s low to close at 46,263.17 levels, up by 9.71 points or by a mere 0.02 per cent. Nifty gained by 9.70 points or 0.07 per cent to settle at 13,567

BSE EBIX Beta Launches Term Insurance for ICICI a Pari on its On-Demand Hi-Tech Platform

DSIJ Intelligence 0 1501 Article rating: 1.7

BSE Ebix Insurance Broking Private Limited, a joint venture of BSE and Ebix Fincorp Exchange Pte Ltd., today announced the beta launch of term Insurance of ICICI Prudential Life Insurance Co. Ltd. on its state-of-the-art hi-tech platform.

Can lingering concerns about rising Coronavirus cases & fear of fresh lockdown imposition put full stop to bull express?

DSIJ Intelligence-3 0 858 Article rating: 5.0

Even though the markets ended in green on Monday, volatility was the hallmark of the session as India VIX rose by 3.25 to 19.40. Further, multiple indecisive candle formations on the daily chart signalled that the dominant bulls are witnessing a slowdown in their pace of ascending.

Nifty trend for Tuesday

DSIJ Intelligence-3 0 1207 Article rating: 4.5

Overall, Nifty seems to move slowly and gradually in the northward directions but with the formation of multiple indecisive candles in the last couple of trading sessions, it clearly indicates that the momentum is dwindling and if the indecisive bars get a confirmation (by closing below the prior bar low), the bears would smell the blood.

Sensex, Nifty at record highs; Burger King gains 131 per cent on listing debut, ONGC jumps 5 per cent, Adani Green declines

DSIJ Intelligence 0 1846 Article rating: 3.8

Markets ended close to record highs as Sensex gained by 154.45 points or by 0.34 per cent to settle at 46,253.46 levels while Nifty rose by 44.30 points or 0.33 per cent to close at 13,558.15 levels.

Cipla rises more than 4 per cent after settling over cancer drug Revlimid; earnings likely to boost

DSIJ Intelligence 0 1147 Article rating: 4.0

Cipla has settled its patent litigation with Celgene over the blockbuster cancer drug Revlimid. Celgene Corporation, a subsidiary of Bristol Myers Squibb, has agreed to provide Cipla with a licence to Celgene’s required patents. Cipla can then sell or manufacture certain volume-limited amounts of generic Lenalidomide in the United States sometime after March 2022.

European Commission expresses positive opinion on rapid-acting insulins of Biocon Biologics

DSIJ Intelligence 0 1511 Article rating: 5.0

A subsidiary of Biocon Limited i.e. Biocon Biologics and Mylan, a subsidiary of Viatris Inc., have received a positive opinion from European Medicines Agency's committee for medicinal products for human use (CHMP), recommending approval of the market authorisation of Kixelle, a biosimilar Insulin Aspart, which is rapid-acting insulin for the treatment of type 1 and 2 diabetes.

RSS
First317318319320322324325326Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR